| | |
Page
|
| |||
| | | | 2 | | | |
| | | | 6 | | | |
| | | | 10 | | | |
| | | | 21 | | | |
| | | | 29 | | | |
| | | | 31 | | | |
| | |
|
| | ||
| | |
|
| | ||
| | | | 34 | | |
|
Proposal 1: Elect Directors
|
| | As this is an uncontested election of directors, the director nominees must receive a greater number of shares voted FOR their election than shares voted AGAINST such election (i.e., a “majority” of the votes cast) to be elected directors. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote shares held by the firms in street name for the election of directors without instructions from beneficial owners. As a result, any shares not voted by a beneficial owner will be treated as broker non-votes. Such broker non-votes will have no effect on the results of this vote. | |
|
Proposal 2: Ratify Selection of our Independent Registered Public Accounting Firm
|
| | The affirmative vote of a majority of the shares cast for this proposal is required to ratify the selection of our independent registered public accounting firm. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote shares held in street name on this proposal without instructions from beneficial owners. As a result, we do not expect there will be | |
| | | | any broker non-votes on this matter. We are not required to obtain the approval of our stockholders to select our independent registered public accounting firm. However, if our stockholders do not ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020, the Audit Committee of the Board of Directors will reconsider its selection. | |
Name and address of beneficial owner(1)
|
| |
Number of shares
beneficially owned |
| |
Percentage of shares
beneficially owned |
| ||||||
5% or greater stockholders: | | | | | | | | | | | | | |
Entities Affiliated with New Enterprise Associates(2)
|
| | | | 11,890,138 | | | | | | 24.8% | | |
Entities Affiliated with Biotechnology Value Fund, L.P.(3)
|
| | | | 3,755,553 | | | | | | 7.8% | | |
Entities Affiliated with Sarissa Capital Management LP(4)
|
| | | | 3,750,000 | | | | | | 7.8% | | |
Entities Affiliated with Venrock Healthcare Capital Partners II, L.P.(5)
|
| | | | 2,483,903 | | | | | | 5.2% | | |
Entities Affiliated with BlackRock Inc.(6)
|
| | | | 2,465,319 | | | | | | 5.1% | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Lawrence M. Alleva(7)
|
| | | | 48,773 | | | | | | *% | | |
Willard H. Dere, M.D.(8)
|
| | | | 29,768 | | | | | | *% | | |
Brian DeSchuytner(9)
|
| | | | 4,453 | | | | | | *% | | |
Andrew A. F. Hack, M.D., Ph.D.(10)
|
| | | | 52,430 | | | | | | *% | | |
Kristen Hege, M.D.(11)
|
| | | | 65,334 | | | | | | *% | | |
Martin Huber, M.D.
|
| | | | 0 | | | | | | 0 | | |
Dirk Huebner, M.D.(11)
|
| | | | 48,526 | | | | | | *% | | |
David Mott(13)
|
| | | | 46,831 | | | | | | *% | | |
Anna Protopapas(14)
|
| | | | 1,357,572 | | | | | | 2.8% | | |
All executive officers and directors as a group (12 persons)(15)
|
| | | | 2,550,851 | | | | | | 5.3% | | |
Name
|
| |
Age
|
| |
Position
|
| |||
Willard H. Dere | | | | | 66 | | | | Director (Class I) | |
Martin Huber | | | | | 60 | | | | Director (Class I) | |
Andrew A. F. Hack | | | | | 46 | | | | Director (Class II) | |
Kristen Hege | | | | | 56 | | | | Director (Class II) | |
Lawrence M. Alleva | | | | | 70 | | | | Director (Class III) | |
David Mott | | | | | 54 | | | | Chair of the Board of Directors (Class III) | |
Anna Protopapas | | | | | 55 | | | | Director (Class III); Chief Executive Officer and President | |
Name
|
| |
Audit Committee
|
| |
Compensation
Committee |
| |
Nominating and
Corporate Governance Committee |
| |||||||||
Lawrence M. Alleva
|
| | | | X(1) | | | | | | | | | | | | X | | |
Willard H. Dere
|
| | | | X | | | | | | | | | | | | X(1) | | |
Andrew A.F. Hack
|
| | | | X | | | | | | X | | | | | | | | |
Kristen M. Hege
|
| | | | | | | | | | X | | | | | | | | |
Martin H. Huber
|
| | | | | | | | | | | | | | | | X | | |
Dave M. Mott
|
| | | | | | | | | | X(1) | | | | | | | | |
Name
|
| |
Age
|
| |
Position
|
|
Anna Protopapas | | |
55
|
| | Chief Executive Officer and President; Director (Class III) | |
Brian DeSchuytner | | |
42
|
| | Senior Vice President, Finance & Product Strategy | |
Dirk Huebner, M.D. | | |
57
|
| | Chief Medical Officer | |
Eva M. Jack | | |
52
|
| | Chief Business Officer | |
Michael Kaufman, Ph.D. | | |
62
|
| | Senior Vice President of Chemistry, Manufacturing and Controls | |
Timothy B. Lowinger, Ph.D.
|
| |
56
|
| | Chief Science and Technology Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total
($) |
| |||||||||||||||||||||
Anna Protopapas
Chief Executive Officer and President |
| | | | 2019 | | | | | | 533,000 | | | | | | 400,000 | | | | | | 506,645 | | | | | | 293,150 | | | | | | 7,000 | | | | | | 1,739,795 | | |
| | | 2018 | | | | | | 515,000 | | | | | | — | | | | | | 1,879,900 | | | | | | 206,000 | | | | | | 6,000 | | | | | | 2,606,900 | | | ||
Dirk Huebner, M.D.(5)
Chief Medical Officer |
| | | | 2019 | | | | | | 460,000 | | | | | | 160,000 | | | | | | — | | | | | | 520,800(6) | | | | | | 7,000 | | | | | | 1,147,800 | | |
Brian DeSchuytner(7)
Senior Vice President, Finance & Product Strategy |
| | | | 2019 | | | | | | 180,013 | | | | | | — | | | | | | 637,128 | | | | | | 78,432 | | | | | | — | | | | | | 895,573 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Number of
securities underlying unexercised options exercisable (#) |
| |
Number of
securities underlying unexercised options unexercisable (#) |
| |
Option
exercise price ($/share) |
| |
Option
expiration date |
| |
Number of
Shares or Units of Stock that Have Not Vested (#) |
| |
Market
Value of Shares or Units of That Have Not Vested(1) ($) |
| ||||||||||||||||||
Anna Protopapas
|
| | | | 748,366 | | | | | | 0 | | | | | | 1.53 | | | | | | 5/7/2025 | | | | | | | | | | | $ | | | |
| | | 129,154 | | | | | | 29,804(2) | | | | | | 4.1 | | | | | | 8/29/2026 | | | | | | | | | | | $ | | | |||
| | | 45,832 | | | | | | 20,834(3) | | | | | | 6.98 | | | | | | 3/13/2027 | | | | | | | | | | | $ | | | |||
| | | 87,500 | | | | | | 112,500(4) | | | | | | 14.23 | | | | | | 2/1/2028 | | | | | | | | | | | $ | | | |||
| | | 40,780 | | | | | | 176,720(5) | | | | | | 3.51 | | | | | | 1/22/2029 | | | | | | | | | | | $ | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 100,000(6) | | | | | $ | 573,000 | | | ||
Dirk Huebner, M.D.
|
| | | | 25,000 | | | | | | 75,000(7) | | | | | | 5.3 | | | | | | 11/29/2028 | | | | | | | | | | | $ | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 40,000(8) | | | | | $ | 229,200 | | |
Brian DeSchuytner
|
| | | | 0 | | | | | | 240,000(9) | | | | | | 3.99 | | | | | | 7/9/2029 | | | | | | | | | | | $ | | | |
Name(1)
|
| |
Fees Earned or
Paid in Cash ($)(2) |
| |
Option
Awards ($)(3) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Lawrence M. Alleva
|
| | | | 21,500 | | | | | | 105,071(2) | | | | | | — | | | | | | 126,571 | | |
Willard Dere, M.D.
|
| | | | 18,000 | | | | | | 105,071(2) | | | | | | — | | | | | | 123,071 | | |
Andrew A. F. Hack, M.D., Ph.D.
|
| | | | 50,000 | | | | | | 68,120(3) | | | | | | — | | | | | | 118,120 | | |
Kristen Hege, M.D.
|
| | | | 42,500 | | | | | | 68,120(2) | | | | | | — | | | | | | 110,620 | | |
David Mott
|
| | | | 12,500 | | | | | | 136,742(2) | | | | | | — | | | | | | 149,242 | | |
Name
|
| |
Cash Fees paid in
the form of Stock Options ($) |
| |
Shares Subject to
Stock Options In respect of Cash Fees (#) |
| ||||||
Lawrence M. Alleva
|
| | | | 35,000 | | | | | | 13,619 | | |
Willard Dere, Ph.D.
|
| | | | 35,000 | | | | | | 13,619 | | |
David Mott
|
| | | | 65,000 | | | | | | 25,292 | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options and rights (a)(1) |
| |
Weighted average
exercise price of outstanding options and rights (b)(2) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)(3) |
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 4,720,772 | | | | | $ | 5.24 | | | | | | 1,786,672 | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 4,720,772 | | | | | $ | 5.24 | | | | | | 1,786,672(4) | | |
Fee Category
|
| |
2018
|
| |
2019
|
| ||||||
Audit Fees
|
| | | $ | 828,830(1) | | | | | $ | 612,571(1) | | |
Audit-Related Fees
|
| | | $ | — | | | | | $ | — | | |
Tax Fees(2)
|
| | | $ | 22,910 | | | | | $ | 84,290 | | |
All Other Fees
|
| | | $ | — | | | | | $ | — | | |
Total Fees
|
| | | $ | 851,740 | | | | | $ | 696,861 | | |